Prestige Biologics (Korea) Probability of Future Stock Price Finishing Over 5,823

334970 Stock  KRW 4,550  130.00  2.78%   
Prestige Biologics' future price is the expected price of Prestige Biologics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Prestige Biologics Co performance during a given time horizon utilizing its historical volatility. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
  
Please specify Prestige Biologics' target price for which you would like Prestige Biologics odds to be computed.

Prestige Biologics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Prestige Biologics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Prestige Biologics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Prestige Biologics generated a negative expected return over the last 90 days
Prestige Biologics has high historical volatility and very poor performance
The company reported the revenue of 3.23 B. Net Loss for the year was (39.38 B) with loss before overhead, payroll, taxes, and interest of (2.88 M).
Prestige Biologics Co has accumulated about 36.77 B in cash with (25.87 B) of positive cash flow from operations.

Prestige Biologics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Prestige Stock often depends not only on the future outlook of the current and potential Prestige Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Prestige Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding47.2 M
Cash And Short Term Investments36.8 B

Prestige Biologics Technical Analysis

Prestige Biologics' future price can be derived by breaking down and analyzing its technical indicators over time. Prestige Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Prestige Biologics Co. In general, you should focus on analyzing Prestige Stock price patterns and their correlations with different microeconomic environments and drivers.

Prestige Biologics Predictive Forecast Models

Prestige Biologics' time-series forecasting models is one of many Prestige Biologics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Prestige Biologics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Prestige Biologics

Checking the ongoing alerts about Prestige Biologics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Prestige Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Prestige Biologics generated a negative expected return over the last 90 days
Prestige Biologics has high historical volatility and very poor performance
The company reported the revenue of 3.23 B. Net Loss for the year was (39.38 B) with loss before overhead, payroll, taxes, and interest of (2.88 M).
Prestige Biologics Co has accumulated about 36.77 B in cash with (25.87 B) of positive cash flow from operations.

Other Information on Investing in Prestige Stock

Prestige Biologics financial ratios help investors to determine whether Prestige Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prestige with respect to the benefits of owning Prestige Biologics security.